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ABSTRACT 
The aetiology of cancer involves intricate cellular and molecular mechanisms that apparently 
emerge on the short timescale of a single lifetime. Some of these traits are remarkable not 
only for their complexity, but also because it is hard to conceive selection pressures that 
would favour their evolution within the local competitive microenvironment of the tumour. 
Examples include ‘niche construction’ (re-programming of tumour-specific target sites) to 
create permissive conditions for distant metastases; long-range feedback loops of tumour 
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growth; and remarkably ‘plastic’ phenotypes (e.g. density-dependent dispersal) associated 
with metastatic cancer. These traits, which we term ‘paradoxical tumour traits’, facilitate the 
long-range spread or long-term persistence of the tumours, but offer no apparent benefit, and 
might even incur costs in the competition of clones within the tumour. We discuss three 
possible scenarios for the origin of these characters: somatic selection driven by specific 
selection regimes; non-adaptive emergence due to inherent vulnerabilities in the organism; 
and manipulation by putative transmissible agents that contribute to and benefit from these 
traits. Our work highlights a lack of understanding of some aspects of tumour development, 
and offers alternative hypotheses that might guide further research. 
 
Key words: evolutionary medicine, cancer, tumour evolution, paradoxical tumour traits, 
somatic selection, oncogenic agents. 
 
CONTENTS 
I. Introduction....................................................................................................................................................................... 3 
II. Paradoxical tumour traits: an evolutionary conundrum .................................................................................... 4 
(1) Distant niche construction ............................................................................................................................ 4 
(2) Long-range positive feedback loops of tumour growth ....................................................................... 5 
(3) Local niche construction ............................................................................................................................... 6 
(4) Metastatic potential – phenotypic plasticity ............................................................................................ 7 
III. Specific selection regimes ......................................................................................................................................... 8 
IV. Inherent vulnerability ............................................................................................................................................... 11 
V. Putative transmissible agents .................................................................................................................................. 14 
(1) The adaptive continuum of pathogen-associated cancer ................................................................... 17 
 3 
VI. How to distinguish? .................................................................................................................................................. 22 
VII. Context and implications ....................................................................................................................................... 24 
VIII. Conclusions .............................................................................................................................................................. 28 
IX. Acknowledgements ................................................................................................................................................... 30 
X. References ..................................................................................................................................................................... 30 
 
I. INTRODUCTION 
The complexity of tumour phenotypes poses a puzzle from the perspective of evolutionary 
biology (Gatenby & Gillies, 2008; Davies & Lineweaver, 2011; Thomas et al., 2017). In the 
time span of at most a few decades, the descendants of a normal cell of a multicellular 
organism can apparently develop complex ways to manipulate neighbouring (Whiteside, 
2008; Hanahan & Coussens, 2012) or even distant (Kaplan et al., 2005; Peinado et al., 2017) 
cells to promote their growth and spread, to form organized structures that have been likened 
to ‘organs’ (Egeblad, Nakasone & Werb, 2010), and to break out of the strict control of 
growth in both space and time. The current paradigm of ‘internal Darwinism’ (Davies & 
Lineweaver, 2011) holds that these complex traits emerge by somatic evolution, driven by 
predominantly cell-level selection, at the expense of the multicellular organism (Nowell, 
1976; Merlo et al., 2006; Greaves & Maley, 2012). However, it has been argued that the 
apparent ‘ease’ of evolving these traits must require special conditions that predispose to the 
convergent evolution of cancer in the many independent instances (Gatenby & Gillies, 2008; 
Davies & Lineweaver, 2011; Thomas et al., 2017). 
The power of evolution often defies intuition, and tends to be underestimated. However, in 
the evolution of cancer within the host, it is not only the rate, but also the nature of adaptation 
that needs to be explained. While somatic evolution towards ‘selfish’ traits, such as clonal 
immortality and unlimited cell division, is so evident that it is the general success of the 
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control mechanisms that requires explanation (Michod, 2003; Pradeu, 2013), the origin of 
some cancer traits cannot be explained easily by the simple forces of cell-level selection, or 
even by the evolution of cooperation between tumour cell clones (Axelrod, Axelrod & Pienta, 
2006; Cleary et al., 2014). 
We structure our paper by presenting first a list of phenomena that we think pose a problem 
within the established paradigm of somatic selection, and then proceeding to discuss three 
possible, not mutually exclusive, explanations that might resolve the problems. 
 
II. PARADOXICAL TUMOUR TRAITS: AN EVOLUTIONARY CONUNDRUM 
Below we list some examples of the tumour traits that we term ‘paradoxical’, because they 
appear to contradict the logic of somatic selection. We discuss the difficulty of explaining 
each of these traits with local selection pressure. 
 
(1) Distant niche construction 
Kaplan et al. (2005) introduced the concept of the ‘pre-metastatic niche’ as a “tumour-
conducive microenvironment at distant sites that arises in response to factors released by the 
primary tumour” (Murgai et al., 2017, p. 1176), often displaying characteristic site specificity 
according to tumour type (Hoshino et al., 2015; Peinado et al., 2017). For example, 
pancreatic cancer has been observed to initiate pre-metastatic niche formation in the liver 
(Costa-Silva et al., 2015), breast cancer in the bones (Cox et al., 2015), renal cancer in the 
lung (Grange et al., 2011), and melanoma in multiple tissues (Kaplan et al., 2005; Peinado et 
al., 2012). The effect of the tumour cells on distant tissues is mediated typically by exosomes 
released by the tumour (Costa-Silva et al., 2015; Grange et al., 2011; Peinado et al., 2012; 
Hoshino et al., 2015). The evolutionary conundrum arises because sharing the benefit of the 
effect (having daughter cells that successfully colonize the constructed permissive 
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environment) is not linked to contributing to its cost (production of exosomes) (Fig. 1A). No 
mechanism is known at the moment that would restrict the colonization of the affected distant 
sites to the progeny of those cells that ‘paid the cost’ for distant niche construction at the site. 
However, if the cells producing the effect enjoy the same benefit as ‘free-riding’ competitors, 
then the cost of the effect incurs a selective disadvantage, and the capacity for distant niche 
construction will be selected against in the within-host somatic evolution of the tumour 
(Tabassum & Polyak, 2015). Therefore, this trait is not only complex, but appears to 
contradict the expected direction of selection in tumour evolution. The systemic suppression 
of anti-metastatic immune responses by a tumour-induced mechanism, observed in a mouse 
model of breast cancer (Coffelt et al., 2015), follows the same evolutionary logic. 
 
(2) Long-range positive feedback loops of tumour growth 
In mouse models of prostate (Park et al., 2013) and lung (Engblom et al., 2017) cancer, 
primary tumour cells were able remotely to activate bone-resident osteoblasts, which then 
triggered the production of specific tumour-infiltrating myeloid cells that promoted the 
growth of the primary tumour. Similar to distant niche construction, the benefits of these 
long-range feedback effects seem to be shared equally between cells that contribute to the cost 
and cells that do not, thus presenting the same evolutionary conundrum (Fig. 1B): if producer 
and non-producer cells compete with each other, the cost of production burdens only the 
former, and all else being equal, these cells should be lost. 
Both distant niche construction and long-range positive feedback loops pose a qualitative 
problem for explanations by somatic selection: not only do they require intricate mechanisms 
that might be hard to evolve, they are expected to be selected against in the within-host 
competition of tumour cell clones. In the following we list some further cancer traits that pose 
a quantitative problem: while they do confer a selective advantage within the host, their 
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evolution might require specific selection regimes or a timescale longer than that of within-
host tumour progression. 
 
(3) Local niche construction 
The growth of tumours is often facilitated by the re-programming of neighbouring cells 
towards tumour-promoting phenotypes to create a supportive local microenvironment 
(Whiteside, 2008; Hanahan & Coussens, 2012). Tumour-associated macrophages (TAMs) 
(Pollard, 2004) and carcinoma-associated fibroblasts (CAFs) (Kalluri & Zeisberg, 2006) are 
characteristic examples of the re-programmed cell types. Because the benefits are indirect 
(non-cell-autonomous), the evolution of these mechanisms is also affected by the problem of 
shared ‘public goods’ (Tomlinson & Bodmer, 1997; Nagy, 2004), although to a lesser extent 
than in the case of the long-range mechanisms listed above. The diffusion of both those 
secreted factors that re-program the microenvironment, and of the tumour-promoting factors 
produced by the manipulated cells, weakens the association between paying the cost and 
reaping the benefit of the niche construction mechanisms (Fig. 1C). This partial decoupling 
reduces, or, depending on the balance of cost and shared benefit, might even fully abrogate 
the selective advantage of these traits. In addition, the ability to re-program other cells (of 
several cell types) is likely to be more difficult to evolve than altering the metabolism, growth 
or motility of the cancer cell itself, as is associated with the general hallmarks of cancer 
(Hanahan & Weinberg, 2000). As the non-tumour cells in the microenvironment are typically 
not mutated (Qiu et al., 2008), re-programming must rely on epigenetic mechanisms, while 
the transformation of the cancer cells can take advantage of genetic changes as well. 
Furthermore, all manipulations must occur through cell-to-cell communication, which is 
inevitably constrained compared with regulatory pathways within the cell. We finally note 
that there is a smooth gradient between ‘local’ and ‘distant’ niche construction, e.g. the 
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suppression of immune cells by tumour-derived exosomes can act both locally and at the 
systemic level (Whiteside, 2016). 
 
(4) Metastatic potential – phenotypic plasticity 
In addition to the non-cell-autonomous tumour mechanisms discussed above, metastasis, the 
ability of tumours to colonize distant tissues (and a hallmark of malignant progression), is 
also in apparent contradiction with the selection forces that act in the local competitive 
microenvironment (Bernards & Weinberg, 2002). The traits required for cellular motility and 
efficient invasion are likely to differ from, and might well conflict with those that aid 
competition within the local microenvironment. It has been argued (Gatenby & Gillies, 2008), 
and also supported by simulations (Aktipis, Maley & Pepper, 2012), that in advanced stages 
of cancer, metastasis might confer a selective advantage by enabling cells to move away from 
a local site where tumour growth has depleted local resources. However, there are two 
potential problems with this reasoning. First, the development of micrometastases and 
circulating tumour cells seems to occur already in the early, asymptomatic stages of cancer 
progression (Pantel, Alix-Panabières & Riethdorf, 2009; Friberg & Nystrom, 2015), when the 
local microenvironment might not yet be depleted. Second, while selection for local growth 
occurs continuously through all cell divisions in a tumour, the traits that promote distant 
metastases are exposed to selection only once in each cycle of metastasis formation. If there is 
conflict (evolutionary trade-off) between the traits required for local growth and 
metastasizing, the former is likely to dominate the evolutionary dynamics. 
To exacerbate the problem, the evolution of metastatic potential is often not a simple 
directional shift from fixed towards mobile cells, but involves the evolution of complex 
phenotypic plasticity. Epithelial tumour cells can undergo a reversible epithelial-to-
mesenchymal transition to alternate between motile/invasive and local growth behaviour 
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(Batlle & Clevers, 2017), and density-dependent tumour cell migration (an efficient adaptive 
dispersal strategy) has been observed with several tumour cell lines (Jayatilaka et al., 2017). 
The evolution of such complex strategies is unlikely in the timespan of tumour progression 
within the host (Arnal et al., 2015). Although we note that cell lines have evolved by serial 
passages over extended periods; density-dependent motility remains to be demonstrated in 
primary tumour cells. 
Thus far we have discussed why simple adaptationist explanations fail to account for the 
recurrent emergence of these complex tumour traits (summarized in Table 1). Below (see also 
Table 1) we investigate what specific circumstances might drive the somatic selection of these 
characters, and then we proceed to alternative explanations. 
 
III. SPECIFIC SELECTION REGIMES 
It is not impossible to conceive selection regimes that could drive the emergence of any one 
paradoxical tumour trait; however, each of the traits requires specific conditions to be under 
positive selection within the organism. 
Easier to tackle are the traits that involve quantitative problems for somatic selection. The 
ability for local niche construction can be selected if the action radius of the tumour-
promoting effect is sufficiently small, such that the net benefit of a producer cell (locally 
strong positive effect minus the cost of production) exceeds the benefit, decreasing with 
distance, that non-producer cells in the neighbourhood receive. Beyond this trivial possibility, 
it has been shown by mathematical modelling that producer cells can persist in a tumour if the 
benefit from the tumour-promoting effect scales with the concentration of producers 
according to a biologically plausible (sigmoid) non-linear function (Archetti, 2013). Such 
scaling creates frequency-dependent selection that favours producers when they are rare, 
which results in stable coexistence of producer and non-producer cells. This scenario has 
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received experimental support regarding the production of growth factors that affect both 
producer and non-producer cells (Archetti, Ferraro & Christofori, 2015). It remains to be seen 
whether the concept applies also to the more complex functions of local niche construction, 
including the reprogramming of neighbouring stromal cells. 
Regarding metastatic potential involving adaptive phenotypic plasticity, we argued that such 
complex dispersal strategies are unlikely to evolve when metastases are rare events, and 
competition for local growth is likely to be the dominant force of selection. By contrast, 
repeated cycles of metastases could impose an alternating selection regime capable of 
selecting for adaptive dispersal. ‘Metastases of metastases’ have long been known to occur 
(Roth, Silverstein & Morton, 1976), and ‘self-seeding’, i.e. metastases between existing 
tumours (Gundem et al., 2015; Kim et al., 2009), might enable covert chains of serial 
metastases. Further research is needed to determine whether such chains indeed precede the 
development of clinically manifest metastatic cancer. Furthermore, metastatic ability might 
evolve as a by-product of local motility if the latter can be selected, e.g. due to metabolic 
demands (Aktipis et al., 2012). However, it then needs to be explained that at least some 
tumour types appear to bypass nearby dissemination, and form distant metastases from the 
beginning (Pantel & Brakenhoff, 2004). 
Long-range mechanisms like distant niche construction and long-range positive feedback 
loops present even harder ‘qualitative’ hurdles for the somatic selection paradigm. In these 
cases, the production (and cost) of the promoting effects appears to be completely decoupled 
from the benefit that arises either at a distant anatomical site or as a systemic, and therefore 
equally distributed, effect. This is a fundamental difference from locally acting mechanisms, 
in which some of the benefit remains private to the producer cells, and sharing is incomplete. 
Notably, the mathematical and simulation models that implement competitive interaction 
events between producer and non-producer cells (Tomlinson & Bodmer, 1997; Archetti, 
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2013) involve incomplete sharing, and therefore do not apply in this setting. With complete 
sharing, non-producer cells that equally share the benefit but do not pay the cost will trivially 
outcompete producer cells, even though the overall growth or spread of the tumour would 
increase with higher proportion of the producer type. 
Distant niche construction and other systemic mechanisms that promote the growth or spread 
of tumours could be explained by somatic selection only if one of two conditions is fulfilled. 
Either, (1) the benefits should be targeted preferentially to the cells that contributed to the cost 
(that is, sharing should be incomplete). In the case of distant niche construction, the cells that 
produce the re-programming factors should have ‘priority’ in the colonization of the 
constructed distant niche; in the case of positive feedback loops, the growth-promoting effect 
should be targeted selectively to the cells that initiate the effect. However, such linkage has 
not been demonstrated yet, and it is unclear how it should emerge and why it would not be 
vulnerable to ‘cheater’ variants that only carry the trait responsible for reaping the benefit. 
Alternatively, (2) the mechanisms of long-range effects could be selected if they conferred 
some local selective advantage, and the distant action emerged as a mechanistically coupled 
‘fortuitous’ side-effect. For example, if distant niche construction depended on the same 
signals that contribute to the re-programming of the local tumour microenvironment in the 
primary tumour, then local selection for the latter also would give rise to the former as an 
‘accidental’ by-product. Furthermore, the production of re-programming factors could confer 
a direct benefit in terms of the ability to metastasize, if circulating producer cells were able to 
facilitate their own engraftment by locally manipulating the anatomical site where they arrive. 
Repeated cycles of metastases could then give rise to this ability, and ‘distant niche 
construction’ could emerge as a side effect of the local manipulating function (due to systemic 
diffusion of the effector molecules). Such coupling cannot be excluded for the observed long-
range positive feedback loops either, and it has also been proposed to explain the evolution of 
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metastatic potential (Bernards & Weinberg, 2002). However, as far as we are aware, there is 
at the moment no empirical support for this scenario. In a mouse model of melanoma, the 
early induction of distant pre-metastatic niches appeared to be uncoupled from 
lymphangiogenesis at primary lesions (Olmeda et al., 2017), which argues against a simple 
mechanistic coupling between local and distal action mechanisms. 
In all, while hypothetical scenarios based on somatic selection can be devised for all 
‘paradoxical tumour traits’, each of these scenarios requires specific conditions to apply 
(Table 1). In particular, the by-product scenario of long-range effects requires coupling 
between local and distal effects, which cannot be an evolved property of the tumour, but 
might exist only as an accidental ‘enabling constraint’, encoded in the responsiveness of non-
tumour cells to molecular signals. In the next section we ask whether such reliance on non-
selected features can be taken further, assuming inherent vulnerabilities in the organism that 
can be ‘discovered’ by essentially neutral evolution of the tumour. 
 
IV. INHERENT VULNERABILITY 
Wu et al. (2016) pointed out that neutral evolution should always be regarded as the null 
hypothesis in the study of evolutionary processes, including those involved in cancer. Indeed, 
while somatic selection clearly plays an important role in tumour progression, genomic 
analyses have also revealed a surprisingly strong signature of neutral genetic drift in the 
molecular evolution of tumours (Wu et al., 2016). This is not altogether surprising, 
considering that tumours start from normal cells ‘programmed’ by organismic evolution to 
survive in the organism, to perform some (for the organism) useful functions, and generally to 
exist deeply below the possible proliferative capacity of a eukaryotic cell. As it is evolved 
brakes, rather than internal limitations that restrict the growth of the cells (Ewald & Swain 
Ewald, 2013), there might be ample room for mutational divergence that does not severely 
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jeopardize the fitness of the cell, including the loss of functions originally provided for the 
organism but dispensable for the cell, but also functions gained. In the early stages of 
oncogenic selection sensu Ewald & Swain Ewald (2013), rare precancerous cells might 
compete not so much with each other, but with the prevalent non-mutated cells of the 
surrounding tissues, which could substantially mitigate the selective costs of paradoxical 
tumour traits. In the following we ask whether neutral evolution might contribute to the 
emergence of these traits in the absence of (strong) selection. 
While the apparently convergent evolution of recurring cancer traits has been likened to 
‘reinventing the wheel’ in each independent instance of cancer (Arnal et al., 2015), the 
evolution of tumour cells has, in fact, easy access to a whole ‘catalogue of wheels’ embedded 
in the host genome. Each precancerous cell starts out with the complete genetic arsenal of the 
multitude of cell types that comprise the host organism, and a vast landscape of cellular 
functions and complexity can be explored by simple regulatory mutations, or even 
epimutations [i.e. stable changes in gene expression in the absence of mutations (Flavahan, 
Gaskell & Bernstein, 2017; Grunau, 2017)]. 
For example, assembling the molecular machinery of local or distant niche construction ‘by 
chance’ seems a priori highly unlikely; however, the necessary components might pre-exist in 
the normal developmental program of the organism, which involves signalling between 
different cells and tissues to initiate commitment to alternative cell fates. For instance, the re-
programming of CAFs might take advantage of a physiological epigenetic program for tissue 
regeneration (Orimo et al., 2005). In turn, phenotypic plasticity in metastases might evolve by 
co-opting a ‘ready-made’ genetic mechanism of epithelial–mesenchymal transition that plays 
a role in embryonic development (Cano et al., 2000). Some combinations of such pre-existing 
components, when ‘stumbled upon’ in the neutral evolutionary trajectories of the 
precancerous cell clones, might give rise to non-cell-autonomous tumour-promoting effects 
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while imposing negligible costs on the cells. In this scenario, selection in the local 
microenvironment would neither aid, nor hinder the emergence of such traits, and the 
evolution of tumour traits is shaped not by positive selection acting on the precancerous cells, 
but by the inherent (‘pre-wired’) vulnerabilities of the organism, resonating with Weinberg’s 
conjecture: “Maybe the information for inducing cancer was already present in the normal 
cell genome, waiting to be unmasked” (Weinberg, 2013, p. 92). 
Importantly, this ‘accidental’ scenario for the emergence of complex tumour traits is not 
incompatible with the recurring nature of particular traits. While the neutral evolution of 
tumours might encompass diverse trajectories, it is very likely that only a small fraction of 
these trajectories point towards complex phenotypes that happen to aid the growth or spread 
of the tumour, and these will then appear repeatedly in the observations. The starting point of 
the trajectories (the original cell type) might also restrict possibilities, resulting in tumour-
type-specific effects, e.g. in the type-specific targeting of metastases that has been highlighted 
in Paget’s classic ‘seed and soil’ metaphor (Paget, 1889). 
To illustrate how inherent vulnerabilities can give rise to apparently complex functions 
without adaptive evolution, we refer to the recent finding that wound healing can induce 
tumour growth at both local and distant anatomical sites (Krall et al., 2018). Using an 
experimental model of breast cancer, they demonstrated that wounding triggers a systemic 
inflammatory reaction that involves the mobilization of myeloid cells that in turn infiltrate 
tumours and promote tumour growth, probably by suppressing anti-tumour adaptive 
immunity. All of these steps appear to occur independently of any adaptive traits of the 
tumour. Furthermore, if the presence of a growing tumour can induce systemic inflammation 
(which is again plausible without invoking adaptive tumour traits) then the circle closes to 
form a long-range positive feedback loop of tumour growth. Of note, in this particular case 
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the components of the ‘paradoxical tumour trait’ might all be pre-wired in the physiology of 
the organism, not even requiring a search of the trait space by neutral evolution. 
To summarize, inherent features of the (healthy) cells and tissues of the organism might 
present vulnerabilities that can be exploited by the tumours in surprisingly complicated forms. 
Some vulnerabilities might exist as ‘ready-made’ packages, others might depend on traits 
accessible to tumours at low or negligible cost, through constrained (high-probability) 
trajectories of neutral evolution. Similar to the adaptive explanations, these scenarios also 
require the constellation of rare conditions to apply. In the following we discuss a third 
possible route to the evolution of ‘paradoxical tumour traits’. 
 
V. PUTATIVE TRANSMISSIBLE AGENTS 
A recent analysis estimated that globally about 15% of new cancer cases can be attributed to 
known infectious agents (Plummer et al., 2016), and as yet unidentified oncogenic infections 
might contribute to further cases of cancer (Ewald, 2009). We propose that some paradoxical 
tumour traits might be associated with as yet unknown transmissible agents that both benefit 
from and contribute to at least some stages of carcinogenesis, involving, in particular, the 
emergence of these complex traits. Under this scenario, it is the ability of the agents to induce 
the traits that is under selection, involving selection pressure to maximize long-term 
transmission success. Such selection forces would favour traits that appear ‘altruistic’ (or 
neutral) at the level of within-host competition, but confer a benefit for long-term 
transmission from the host. Furthermore, the time frame for the evolution of these traits 
would extend from a single lifetime (somatic evolution within the host) to the much longer 
timescale of long chains of transmissions among hosts. 
A number of criteria can be formulated for the agent-mediated scenario to work – these can 
also be regarded as predictions for the nature of the putative transmissible agents. First, 
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transmission of the agents must indeed be facilitated by the growth and spread of the affected 
tumour cell clones. In most known oncogenic infections, it is typically assumed that, except 
for the earliest stages of transformation, tumour cells no longer produce the pathogen that 
originally initiated the process, and cancer arises only as a side effect of mechanisms that 
promote the propagation of the infectious agent within the host (Burnet, 1970; Moore & 
Chang, 2010; Ewald, 2009; Ewald & Swain Ewald, 2015). In apparent contrast, the 
transmissible agents presumed to be responsible for paradoxical tumour traits should benefit, 
i.e. they should be produced from tumour cells at least up to the stage where these traits 
emerge. In particular, metastatic spread should also be beneficial for the agents, either simply 
by increasing their production, or by facilitating transmission to other individuals. These 
conditions are required to create selection pressure for the capacity to induce the observed 
paradoxical tumour traits. As we will explain below, the putative agents are likely to take 
advantage of the early, asymptomatic dissemination of tumour cells, which weakens the 
apparent contrast. 
Second, the agents must possess mechanisms that code for, or facilitate the emergence of 
these tumour traits (going beyond the capacity of known oncogenic agents that can 
immortalize infected cells). Kaposi’s sarcoma-associated herpesvirus (KSHV) contributes to 
the construction of tumour microenvironment in Kaposi’s sarcoma by reprogramming 
adjacent (uninfected) cells via the exosomal transfer of regulatory microRNA (Yogev et al., 
2017). If unknown infectious agents are responsible for the cancer types that display 
paradoxical tumour traits, they should also possess targeted mechanisms to induce these traits. 
Third, the agents should be highly prevalent and of low virulence. Most cancer types that 
display paradoxical tumour traits (e.g. breast, prostate and pancreatic cancer) do not show 
epidemiological evidence for a transmissible cause. This apparent contradiction can be 
resolved if the causative infections are prevalent in the population, and are necessary, but not 
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sufficient to cause clinically manifest cancer (Ewald, 2000). Under this scenario, the vast 
majority of infections are asymptomatic, and manifest cases of cancer occur either due to rare 
stochastic processes, and/or facilitated by other carcinogenic co-factors. As a necessary 
condition, paradoxical tumour traits should emerge, and the agents should be transmitted 
already in the asymptomatic stages of tumour development (which seems consistent with the 
early development of micrometastases (Friberg & Nystrom, 2015; Pantel et al., 2009)). 
Indeed, symptomatic stages of cancer tend to be associated with progressive illness that is 
likely to limit the contacts of the affected individual, and would thereby strongly curtail the 
transmission of an infectious agent to new hosts, even if the production of the agent within the 
host continues. Between-host transmission is thus predicted to occur primarily in early 
asymptomatic infection. Finally, the requirement for high prevalence implies that the putative 
agents should be highly transmissible, while our failure to identify them indicates that they 
must be hard to detect (although low virulence in itself makes an infectious organism easier to 
miss).  
At this point we can ask whether known infectious agents might fit the profile that we have 
sketched. With a few exceptions, currently known oncogenic pathogens do not seem to 
benefit from the stages of cancer at which paradoxical tumour traits typically emerge, and are 
not known to possess mechanisms that could induce these traits (see Section V.1 for details). 
While some known pathogens might have as yet undiscovered capabilities in this regard (the 
role of KSHV in the construction of the tumour microenvironment was only recently 
described), most cases of paradoxical tumour traits are associated with cancer types where 
even infectious aetiology has not been documented yet. The putative unknown agents might 
be undiscovered relatives of already known oncogenic organisms; e.g. the discovery of an 
expanding family of human polyomaviruses (some of which are associated with cancer risk) 
in the last ten years (Spurgeon & Lambert, 2013) illustrates that there might be a broad array 
 17 
of asymptomatic infectious agents that have remained undetected. Alternatively, our failure to 
detect the putative agents might indicate that they are too divergent from currently known 
infectious organisms to be detected by current assays. In either case, if some paradoxical 
tumour traits are indeed induced by transmissible agents, then these agents can, as we explain 
below, be placed into a continuum of pathogenic life-history strategies. 
 
(1) The adaptive continuum of pathogen-associated cancer 
We argue that there is a continuum in the association between carcinogenesis and the 
transmission (fitness) of the various infectious agents that contribute to it. At one end of the 
spectrum, most of the currently known oncogenic pathogens do not seem to benefit from the 
cancers, which are thought to arise only as a side effect of the presence of the agents, e.g. due 
to mechanisms that promote the propagation of the causative organisms within the host 
(Burnet, 1970; Moore & Chang, 2010; Ewald, 2009; Ewald & Swain Ewald, 2015). In stark 
contrast, some non-human cancers are caused by transmissible tumour cells (Metzger & Goff, 
2016; Ostrander, Davis & Ostrander, 2016; Ujvari, Gatenby & Thomas, 2017), implying that 
the tumour itself has become infectious, and metastasizing is the only way the infectious 
agents can spread. We think that these two extremes enclose a spectrum of gradual transitions, 
and propose the following classification within the continuum. 
In our classification, Class 1 carcinogenic organisms include the pathogens that induce 
carcinogenic effects that do not affect the proliferation or survival of the infected cells; such 
infectious agents are regarded as ‘indirect carcinogens’ (International Agency for Research on 
Cancer, 2012). For example, infection by parasitic helminths is thought to increase the risk of 
cancer in the urinary bladder and other affected organs by promoting chronic inflammation 
that, per se, does not benefit the pathogen (Scholte, Pascoal-Xavier & Nahum, 2018). In other 
cases, the carcinogenic mechanism might affect uninfected cells, e.g. the cytotoxin-associated 
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gene A (CagA) virulence factor of Helicobacter pylori is able to enter and transform cells that 
do not harbour the bacterium (Segal et al., 1999) (H. pylori is predominantly extracellular). In 
these cases, transformed cells do not directly promote the spread of the pathogens.  
Class 2 carcinogenic organisms can induce immortality and/or proliferation of the infected 
host cells, which increases the production of infectious progeny that can be transmitted to new 
hosts. The first stage of neoplastic transformation is thus beneficial for the pathogen, and the 
ability to induce such transformation is shaped by adaptive evolution of the infectious agents. 
However, metastatic cancer arises only occasionally, and is a ‘side-effect’ of relaxed cell-
cycle control and (from the perspective of the pathogen) ‘run-away’ somatic evolution: 
metastatic cells typically no longer produce the pathogen. Epstein-Barr virus, human 
papillomaviruses (HPV), KSHV and Merkel cell polyomavirus (MCV) are probable 
representatives of this class, and while long considered to be indirect inflammatory 
carcinogens, hepatitis B and C viruses have also recently been characterized to encode direct 
carcinogenic mechanisms (Ewald & Swain Ewald, 2012; Irshad, Gupta & Irshad, 2017). 
Importantly, while the expression of certain viral proteins is required for the maintenance of 
the transformed phenotype in these cases, malignant tumours are generally assumed to have 
ceased producing intact virions in either MCV- (Shuda et al., 2008) or HPV- (Steenbergen et 
al., 2014) positive cases [although integrated copies of HPV might occasionally be 
reactivated (Woodman, Collins & Young, 2007)]. This stage likely represents a precarious 
balance for the pathogen: the degree of divergence from the healthy state helps it to persist 
and reproduce, but the weakening of the cellular control mechanisms inevitably entails the 
risk of further divergence towards a cancerous state in which viral replication is lost (Ewald & 
Swain Ewald, 2015). The ability to induce paradoxical tumour traits that aid the proliferation 
and spread of the infected tumour cell clones (e.g. long-range positive feedback loops or local 
niche construction) might evolve in this class. 
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We define Class 3 carcinogenic pathogens as those that retain the ability to produce offspring 
in (at least early-stage) metastatic infected cells. To achieve this, the pathogen must either be 
able to persist in the cells as the tumour acquires metastatic potential by somatic evolution, or 
itself must be capable of inducing metastatic characters while the tumour cell clone still 
preserves much of its genomic stability. In this class, the ability to induce paradoxical tumour 
traits that promote metastasis (distant niche construction, adaptive plasticity of metastatic 
characters) can also evolve. 
The metastatic dissemination of infected cells can benefit a pathogen simply by increasing the 
production and titre of infectious progeny. Possible examples include eukaryotic Theileria 
parasites that induce metastatic dissemination of infected leukocytes by increasing the 
motility and invasiveness of the cells (Ma & Baumgartner, 2014); and jaagsiekte sheep 
retrovirus (JSRV), which causes a transmissible lung tumour of sheep, and is spread primarily 
by virions produced from tumour cells in the lung, but appears also in milk and colostrum, 
indicating some dissemination (Griffiths, Martineau & Cousens, 2010). Remarkably, JSRV 
appears to be able to induce neoplastic transformation in an autonomous fashion: the genetic 
divergence of JSRV-transformed tumour cells is therefore considerably lower compared with 
other tumour types, which is likely to be important for the continued production of virus from 
the transformed cells. Some intracellular bacteria might also follow a similar strategy: 
Fusobacterium nucleatum and other anaerobic bacteria associated with colorectal cancer 
appear to be maintained in distant metastases, spreading along with the cancer cells (Bullman 
et al., 2017). 
In addition to increasing the production of infectious progeny, metastasis can, in some cases, 
also enable the pathogen to invade specific anatomical sites important for onward 
transmission to other hosts. This adds a qualitative dimension to the quantitative benefit 
(production of infectious progeny), and the fitness benefit is realized at the between-host 
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level. Paradoxical tumour traits that enable targeted metastasis might evolve. A possible 
example is Marek’s disease virus, which is suspected to take advantage of transformed 
infected lymphocytes to disseminate to the anatomical sites of onward transmission (Boodhoo 
et al., 2016). 
Finally, in rare cases, in addition to (or instead of) cell-free infectious particles, infected 
tumour cells can also be transmitted between hosts. The capability for metastatic 
dissemination is not an aid, but a strict prerequisite for this transmission route. However, the 
transmitted cells typically act only as vehicles for transmitting the infectious agent, and the 
pathogen can establish infection of the new individual by infecting resident host cells (with 
progeny released from the transmitted cells), rather than by the proliferation of the infected 
cells transmitted from the original host. The ability to induce distant spreading of the 
transformed cells is expected to be under strong selection in such cases. Furthermore, because 
the exchange of cells between individuals typically requires close contact, the pathogens are 
expected to evolve long persistence (and therefore low virulence) in the host, in order to adapt 
to the rare opportunities of transmission (similar to sexually transmitted infections) (Ewald, 
2009). From the known carcinogenic pathogens, human T-cell leukemia viruses (and their 
non-human relatives) belong to this category (Pique & Jones, 2012). 
Finally, we define Class 4 oncogenic pathogens to include transmissible cancer cell clones 
that are the causative organisms of transmissible cancers (Metzger & Goff, 2016; Ostrander et 
al., 2016; Ujvari et al., 2017). Naturally occurring transmissible cancer has been identified in 
three groups of hosts so far: canine transmissible venereal tumour (CTVT) is a sexually 
transmitted tumour in dogs that arose from a single cancer lineage thousands of years ago 
(Murgia et al., 2006); devil facial tumour disease affects Tasmanian devils (Sarcophilus 
harrisii) and consists of at least two independently evolved tumour lineages (Pearse & Swift, 
2006; Pye et al., 2016); and disseminated neoplasia of bivalves affects multiple host species, 
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and evolved at least three times independently (Metzger et al., 2016). In these infections, it is 
the tumour cells themselves that are transmitted between hosts, and the infectious clones can 
be regarded as eukaryotic parasites [indeed, as new species in their own right (Frank, 2007; 
Vincent, 2010)]. In their present form, the known lineages of transmissible cancer appear to 
be fully autonomous: they do not harbour or require genetically independent oncogenic 
agents. However, an infectious aetiology cannot be excluded for the initial transformation of 
the ancestral tumour clone. In fact, cells transformed by Class 3 (or, to a lesser extent, by 
other) oncogenic pathogens might be prone to form transmissible clones, and it might be only 
the efficient elimination of allogeneic host cells that is likely to restrict the evolution of 
transmissible cancers to relatively rare occurrences. In the rare ‘successful’ cases, once a 
tumour cell clone has acquired the ability to be transmitted between hosts, there will be strong 
selection pressure on the cells to eliminate the original oncogenic agent (Ewald, 2009), in 
order to avoid the loss of resources, eliciting immune responses against the agent, and 
genomic instability induced by the oncogenic pathogen. This is likely to happen early after 
the initial transition, implying that the lack of an apparent co-infecting agent is not a strong 
argument against an infectious aetiology in the origin of transmissible cancers. 
We emphasize that the classes in the proposed classification do not represent strict categories, 
but are intended only as illustrative stages of a continuous spectrum. Indeed, pathogens might 
evolve gradually along the spectrum, and the only abrupt transition occurs if transformed cells 
acquire the ability to be transmitted across consecutive host individuals, and evolve into a 
Class 4 oncogenic pathogen. 
In this ‘continuum’ of the degree of linkage between the transmission of infectious agents and 
their oncogenic effect, putative transmissible agents responsible for paradoxical tumour traits 
are expected to belong mostly to Class 2 or 3, in which the causative agents benefit directly 
from some stages of oncogenesis. Transmissible cancers, which are clearly under selection for 
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efficient between-host transmission, might also evolve the ability to induce paradoxical 
tumour traits. However, large-scale cancer genotyping efforts should already have uncovered 
evidence of transmissible tumours if they were a common occurrence in human cancer, 
implying that the paradoxical tumour traits observed in common human cancers are unlikely 
to have such origins. 
Finally, we note that the evolution of the mammalian placenta might have been triggered by 
retroviruses that can be regarded as Class 3 oncogenic pathogens. The trophoblastic cells of 
the placenta resemble cancer in their ability to divide rapidly, migrate, induce vascularization, 
suppress maternal immune rejection and, by these abilities, to effectively invade maternal 
tissues (Soundararajan & Rao, 2004). Remarkably, these properties rely heavily on genes of 
retroviral origin: on syncytins to enable cell fusion and immune suppression (reviewed in 
Denner, 2016), and possibly also on gene regulatory networks (Chuong, 2013). While now 
these genes benefit the host and can be considered to be ‘domesticated’, their expression in 
the placenta probably evolved originally to facilitate retroviral transmission between the 
mother and the foetus (Haig, 2012). The invasive properties of trophoblasts might have 
originated from an earlier stage of evolution in which infected cells were transformed by the 
retroviruses towards an invasive phenotype to create a vehicle for efficient transmission. This 
would have classified these viruses as Class 3 oncogenic pathogens, which would have been 
under selection pressure to induce paradoxical tumour traits. 
 
VI. HOW TO DISTINGUISH? 
We delineated three possible scenarios that could explain the evolution of paradoxical tumour 
traits: specific selection regimes, inherent vulnerabilities, and manipulation by transmissible 
agents. All three alternatives require specific sets of conditions, providing clues for the 
validation and discrimination of the scenarios. The major testable dichotomy is whether a 
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tumour trait arises by autonomous processes within the organism, or is induced by an 
acquired external element. Validation of the agent-mediated scenario requires the 
identification of the agent, and the demonstration of its ability to induce and to benefit from a 
paradoxical tumour trait. 
The scenarios based on selection and inherent vulnerabilities are harder to distinguish. In both 
cases, the mechanisms of tumour traits can arise by mutations and/or epimutations, and there 
is a smooth gradient between no selection and strong selection. Signatures of positive 
selection in the genes responsible for paradoxical tumour traits can be revealing, as can 
convergent evolution in independent instances of cancer (although the latter might involve 
convergence in the phenotype without strong convergence in the genotype; Wu et al., 2016). 
Ultimately, the cost of the traits in the local selective microenvironment can be assessed by in 
vitro competition experiments using cells with manipulated levels of expression of the trait 
(Archetti et al., 2015). However, to proceed to this stage requires first a detailed 
characterization of the genetic background and molecular mechanisms of the paradoxical 
tumour traits. Such an understanding is needed also to recognize coupling between local and 
distal effects, or cases where the trait can emerge from an inherent vulnerability of the 
organism. 
In addition, some predictions can be made also in the absence of a detailed understanding of 
the mechanisms. For example, if paradoxical tumour traits reflect the action of transmissible 
agents, then cancers that are caused by other carcinogenic effects should not display such 
traits, and should, in general, display less (or fewer) complex phenotypes. Testing this 
prediction is, however, sensitive to uncertainties regarding the contribution of infectious 
causes to cancer. 
Another prediction can be formulated regarding genomic instability, which is a hallmark and 
key driver of carcinogenesis (Loeb, 1991). Genomic instability creates variation, which opens 
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up both adaptive and neutral evolutionary trajectories, and thereby increases the capacity and 
‘reach’ of evolutionary processes within the lifetime of the organism. In particular, the 
evolution of tumour traits by somatic selection is expected to occur in the context of 
increasing genomic instability, which aids the exploration of new genotypes. For 
transmissible agents, however, genomic instability makes it harder to retain ‘control’ of the 
host cell: strong within-host selection (aided by enhanced variation) might erode the traits 
responsible for between-host transmission (Levin & Bull, 1994), and the agent itself might be 
eliminated. If feasible, the optimal strategy for the agents is rather a targeted manipulation of 
only those processes that directly promote their spread. As an implication, those tumour types 
that progress to a metastatic stage with fewer mutations (lower degree of genomic instability) 
might be more likely to be initiated by transmissible agents, and the search for the putative 
agents could focus on these types. Similarly, precancerous cells in the early stages of 
transformation are more promising for the search for the agents compared with late-stage cells 
or cell lines that have been strongly re-shaped by somatic selection and genomic instability, 
and are less likely to have retained the initiating agents. 
 
VII. CONTEXT AND IMPLICATIONS 
We have shown that some complex tumour traits are difficult to explain by somatic selection 
not only due to their complexity, but also because local selection in the tumour 
microenvironment is expected to act against these traits. The idea that costly ‘public goods’ 
type traits of cancer might be disfavoured by somatic selection has been brought up and 
analysed previously (e.g. Tomlinson & Bodmer, 1997; Nagy, 2004; Merlo et al., 2006; Tissot 
et al., 2016; Tabassum & Polyak, 2015; Archetti, 2013; Archetti et al., 2015). Most of the 
earlier studies addressed the production of diffusible growth factors; we have extended the 
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arguments to demonstrate the additional difficulties associated with more complex 
‘paradoxical tumour traits’. 
We also note that the difficulty in explaining the origin of paradoxical tumour traits by 
somatic selection is not alleviated by the evolution of local cooperation between tumour cell 
clones, which has been predicted (Axelrod et al., 2006) and demonstrated (Cleary et al., 
2014) to occur. Cooperation can evolve when distinct tumour cell clones provide mutually 
beneficial functions to each other that combine into synergistic fitness gain. By contrast, non-
cell-autonomous paradoxical tumour traits (niche construction, long-range positive feedback 
loops) operate by manipulating non-evolving stromal cells, which excludes such co-
evolutionary mechanisms. 
We developed three possible scenarios that could explain the evolution of these traits, based 
on somatic selection driven by specific selection regimes, inherent vulnerabilities, or 
manipulation by transmissible agents. Importantly, the three scenarios are not mutually 
exclusive. In particular, inherent vulnerabilities can facilitate adaptive evolution by providing 
‘ready-made’ packages of complex functionalities, e.g. phenotypic plasticity or intercellular 
communication. This might apply to both somatic evolution driven by specific selection 
regimes, and to the evolution of transmissible agents that can exploit the vulnerabilities. 
Inherent vulnerability, the ease of repeatedly evolving cancer, has previously been discussed 
in the context of ‘atavism’, arguing that the ancient ‘toolkit’ of the ancestral unicellular 
lifestyle might still exist in the genome of multicellular organisms, and might be unlocked by 
genetic or epigenetic malfunction (Davies & Lineweaver, 2011; Davies & Agus, 2015; 
Vincent, 2012). This hypothesis has recently gained support by genomic and transcriptomic 
analyses showing that neoplastic transformation is indeed associated with a convergent loss of 
multicellularity-associated genes, and a return to a unicellular-like cell state (Chen et al., 
2015; Trigos et al., 2017). Atavistic traits thus indeed appear to facilitate evolution towards a 
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‘selfish’ lifestyle (Thomas et al., 2017), involving cell-autonomous cancer traits such as 
replicative immortality. 
However, the predisposition to revert to atavistic cell states cannot contribute to the 
paradoxical tumour traits that involve non-cell-autonomous effects, and are ‘paradoxical’ 
because they appear to contradict selection for selfish traits. Instead, the inherent 
vulnerabilities relevant to these traits are more likely to stem from functions that evolved in 
conjunction with the multicellular lifestyle. To list some examples, several pathways of 
tumour growth exploit genetic circuitry that is normally active during embryogenesis (Ma et 
al., 2010; Cano et al., 2000) or tissue regeneration (Orimo et al., 2005; Krall et al., 2018); cell 
motility plays an important role in immune surveillance in animals (Ewald & Swain Ewald, 
2015); and placental mammals have evolved invasive properties of trophoblasts to enable 
placentation (Haig, 2015). These capabilities are not atavisms, but have evolved and are 
maintained for functions required for multicellular organisms. As a result, they are more 
amenable to exploitation for ‘cooperative’ functions in cancer. 
On a general note, the diversity of inherent vulnerabilities is likely to scale with the 
complexity of the organism. While cancer-like phenomena occur almost everywhere across 
the tree of life (Aktipis et al., 2015; Albuquerque et al., 2018), complex tumour traits (aided 
by emergent vulnerabilities) are more likely to occur in the organisms with the most complex 
body plans and developmental flexibility. Of note, Burnet (1968) proposed 50 years ago that 
vertebrates, in particular, might pay a price of increased susceptibility to cancer for the 
increased developmental flexibility associated with this lineage. 
How do the possibilities tackled in this paper affect the way we should (or could) treat 
malignant disease? Some implications of somatic selection and inherent vulnerabilities have 
been discussed elsewhere (Thomas et al., 2017). In general, tumour traits that arise by somatic 
selection might be more amenable to selective treatment, as these represent features divergent 
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from the normal physiology of the organism. By contrast, traits arising from inherent 
vulnerabilities comprise components that participate in some normal function, and targeting 
these might run a greater risk of adverse reactions by interfering with essential processes. In 
fact, vulnerabilities that were not coupled to some important function by structural constraints 
are expected to have been weeded out by selection, leaving only those that are protected by 
such coupling. 
Obviously, if some cancer traits are induced by transmissible agents, then identifying and 
eliminating these agents could prevent the development of the affected cases of cancer. Ewald 
(2009, p. 24) estimated that “a causal role for parasitism can be excluded for less than 5% of 
all cancer”. The lack of epidemiological signatures of a contagious cause can be explained if 
the causative organisms are common in the population, and cancer arises only when the 
infectious agent is present in combination with some other predisposing factor, as seems be 
the case with Epstein-Barr virus- and Merkel cell polyomavirus-associated cancers (Moore & 
Chang, 2017). In Ewald’s nomenclature, the infectious agents should comprise an ‘essential’ 
cause of cancer, breaking down key initial barriers to oncogenesis, while further 
‘exacerbating’ factors should be needed for the development of malignant tumours (Ewald & 
Swain Ewald, 2013). In this scenario, most infected individuals never develop clinically 
manifest cancer; however, eliminating transmission would nonetheless eliminate all cases of 
cancer that involve the action of the agent (Fig. 2). 
A potential further implication for treatment might arise if transmissible agents can mediate a 
cumulative evolution of resistance against cancer drugs or radiation therapy. If cancer patients 
were a potential source of transmission, and the evolution of resistance in cancer treatment 
could involve heritable (genetic or epigenetic) traits of the transmissible agent, then these 
changes could be transmitted to new patients, and resistance could increase across the chains 
of transmission, abrogating the efficiency of widely used treatment modalities at the 
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population level. This effect is limited if, as we deem likely, most transmissions occur in the 
pre-clinical stage from asymptomatic carriers. 
Conversely, if ‘paradoxical tumour traits’ turn out to arise by internal evolution, then mapping 
the precise conditions that generate specific selection pressures or inherent vulnerabilities 
might also point to new treatment strategies. 
 
VIII. CONCLUSIONS 
(1) We established that some complex tumour traits are difficult to explain by somatic 
selection not only due to their complexity, but also because they are expected to confer a 
fitness cost, rather than a benefit in the local competitive microenvironment of a tumour. 
Some traits (non-cell-autonomous effects of niche construction and long-range positive 
feedback loops) offer a benefit that is expected to be shared equally by cells contributing to 
the trait, and other clones that did not pay the ‘cost’, excluding the spread of the trait within 
the tumour. Other traits that aid metastases (e.g. adaptive phenotypic plasticity of metastatic 
characters) are expected to be under weak selection, as within-tumour selection is likely to 
dominate the life history of tumour cell clones. We formulated three scenarios that could 
explain, possibly in combination, the recurrent emergence of such ‘paradoxical tumour traits’. 
(2) First, somatic selection can be ‘rescued’ under specific selection regimes that we 
described for each problematic trait. In the case of non-cell-autonomous effects, paradoxical 
tumour traits can evolve if their benefit affects producer cells preferentially, or if the 
distributed long-range effect is coupled (by structural constraints) to some local beneficial 
effect that is focused on the producer cells. Complex traits that aid metastases might evolve if 
metastases occur repeatedly, possibly in a ‘ping-pong’ fashion between different tumour foci. 
(3) Alternatively, (some of) the paradoxical traits might be induced by putative (potentially, 
as yet unknown) transmissible agents that are disseminated by or from infected tumour cells. 
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In this case, the selection pressures moulding these traits would act not (only) at the within-
host level and timescale, but also at the level and timescale of serial transmissions among 
hosts. A pathogen that is able to spread from tumour cells is under selection to evolve traits 
that aid the transformation, growth and dissemination of the infected cells, including traits 
that would incur a net cost in the intra-tumour competition of tumour cell clones. We 
predicted several characteristics of the hypothetical agents, including low virulence, i.e. low 
propensity to cause clinically manifest cancer without additional co-factors; instead, their 
transmission should mostly be aided by the early dissemination of tumour cells, resulting in 
the lack of an epidemiological signature in the diagnosed cases of malignant tumours. The 
existence of such transmissible agents would nonetheless increase the contribution of 
infectious causes to cancer. 
(4) In conjunction with the possible infectious causes of complex tumour traits, we developed 
the framework of an adaptive continuum of pathogen-associated cancer. The continuum refers 
to degrees of association between stages of cancer and the transmission of oncogenic 
pathogens. The spectrum extends from pathogens that cause cancer as an indirect effect, but 
are not propagated in tumour cells, to transmissible tumours in which it is the tumour cell 
clones that are transmitted between hosts. In between are pathogens that contribute to the 
transformation of the infected cells, and are produced in either the local tumour growth or, in 
some cases, also from metastatic cells. Putative transmissible agents responsible for 
paradoxical tumour traits are expected to belong to these intermediate categories. 
(5) Finally, inherent structural, genomic and regulatory components of the organism might 
present vulnerabilities that offer ‘easy’ evolutionary trajectories to complex tumour traits, 
possibly even by neutral drift, or in combination with either somatic selection or transmissible 
agents. The vulnerabilities relevant for complex tumour traits are likely to stem from 
characters originally selected for multicellular lifestyles, rather than from atavisms that 
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resurrect unicellular characters. The level of developmental complexity and plasticity might 
be correlated with the risk and severity of such vulnerabilities, exposing organisms with 
higher developmental complexity (e.g. vertebrates) to a higher burden of cancer. 
(6) We have thus extended the dichotomy of somatic selection and atavism as the explanatory 
framework of tumour evolution (Thomas et al., 2017) in two ways: (1) by widening the scope 
of predisposing factors from atavistic traits to a broader category of inherent vulnerabilities 
(including those emerging from multicellular adaptations), and (2) by adding a third scenario 
based on manipulation by transmissible agents. 
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Table 1. Tumour traits that are problematic to explain by somatic selection. 
Paradoxical 
tumour trait 
Definition Problem with within-host 
selection 
Can be selected within the host 
if: 
Distant niche 
construction 
Factors released by the 
tumour transform a distant 
anatomical site to be 
permissive for metastases 
Qualitative: ‘cheater’ 
clones of the tumour share 
the benefit, while only 
‘niche constructor’ clones 
bear the cost 
the constructed niche is 
preferentially accessible to the 
‘niche constructor’ clones; or 
niche construction arises as a by-
product of a locally beneficial 
trait  
Long-range 
positive 
feedback loops 
Factors released by the 
tumour activate a remote 
mechanism that promotes 
tumour growth by a long-
range, spatially distributed 
effect 
Qualitative: ‘cheater’ 
clones of the tumour 
receive equal share of the 
benefit, while only 
producer clones bear the 
cost 
producer clones benefit 
preferentially from the growth 
feedback effect; or the long-range 
effect arises as a by-product of a 
locally beneficial trait 
Local niche 
construction 
Factors released by the 
tumour reprogram adjacent 
cells to form a supportive 
tumour microenvironment 
Quantitative: ‘cheater’ 
clones share some of the 
fitness benefit, without 
paying the cost 
spatial spreading of the tumour-
promoting effect is strongly 
limited; and/or benefits are non-
linear, creating frequency-
dependent selection 
Metastatic 
potential – 
phenotypic 
plasticity 
Tumour cells acquire the 
ability to leave the tumour 
and colonize distant 
tissues, displaying 
adaptive phenotypic 
plasticity 
Quantitative: antagonistic 
selection for efficient local 
growth is expected to 
dominate clonal evolution; 
few rounds of serial 
metastases 
serial metastases occur more 
frequently than currently realized; 
and/or metastatic potential arises 
as a by-product of a locally 
beneficial trait 
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Fig. 1. Problems with somatic selection for non-cell-autonomous tumour traits. In distant 
niche construction (A), tumour cells release signals (dashed arrows) that target a distant 
anatomical site, re-programming cells to form a permissive microenvironment for the 
invasion of circulating tumour cells. If production of the signal imposes a metabolic cost, 
producer cells (shaded) are selected against in the local microenvironment, while in the 
colonization of the distant niche, non-producer cells receive equal benefit. Somatic selection 
is expected to eliminate the trait. In long-range positive feedback loops (B), tumour cells 
stimulate distal tissue (dashed arrows) to produce systemic factors that promote the growth of 
the tumour. If the cells that produce the stimulus (indicated by shading) receive the same 
growth benefit (solid arrows) in the tumour as non-producer cells, but bear the cost of 
producing the stimulus, somatic selection is expected to eliminate the trait. Finally, in the 
construction of the local tumour microenvironment (C), tumour cells re-program adjacent 
stromal cells to provide supporting functions that facilitate tumour growth. Both the re-
programming signal (dashed arrows) and the growth promoting effects (block arrows) can 
spread in the local neighbourhood, weakening the relative benefit of the producer cells that 
alone bear the cost of the signals. 
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Fig. 2. Schematic representation of the epidemiology of cancer caused by the combination of 
a prevalent infection and additional factors. Chronically infected individuals are indicated by 
grey shading, block arrows denote past transmission events, and curly arrows represent the 
additional factor(s) necessary to trigger cancer. The rare cases of clinically manifest cancer 
(indicated by black shading of the body of the individual) appear only when infected 
individuals are exposed to the additional factor(s), while asymptomatic infections are 
common in the population. As a result, although infections spread along contacts, the cases of 
detectable disease do not cluster substantially in the network. An intervention that blocks 
transmissions (indicated by the striped rectangle) would nonetheless eradicate not only the 
infection, but also the cancer from the population, despite continued exposure to the co-
factor(s). If the dependence of cancer on the infectious agent is not absolute, interventions 
blocking transmission reduce but do not eliminate cancer, while the linkage still remains hard 
to detect. The additional factors required for cancer might involve co-infections, other 
carcinogens, rare genetic predisposition, or low-probability mutation events. 
 
 
 
 
 
 
 
